| Oct 3 |
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
|
| Sep 30 |
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
|
| Sep 27 |
How Many Stocks Should You Own?
|
| Sep 27 |
Tempus AI expands oncology collaboration with Takeda
|
| Sep 26 |
Tempus announces expansion of collaboration with Takeda
|
| Sep 24 |
The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America
|
| Sep 24 |
Takeda’s FRUZAQLA approved in Japan for advanced colorectal cancer
|
| Sep 24 |
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
|
| Sep 24 |
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
| Sep 23 |
MHRA approves Takeda’s fruquintinib for metastatic colorectal cancer
|
